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Background: Differences in oxygen delivery between portable oxygen concentrators (POC)
and liquid oxygen (LO) portable units, pose a question if POCs are equally effective as LOs
in reducing exercise-induced hypoxaemia.
Design: Randomized, single-blind clinical trial.
Patients: Thirteen COPD patients (means: age 66711 year, FEV1 35.2713.7% predicted)
and respiratory failure (means: PaO2 5275mmHg, PaCO2 51.377.5mmHg).
Methods: All patients underwent a series of 6-min walk tests (6MWT) carried out in
random order among one of the three devices: POC, LO cylinder and cylinder with
compressed air (CA). Oxygen supplementation was 3 lpm for LO and an equivalent to 3 lpm
in a pulse ﬂow system for POC.
Results: The mean SpO2 was equally improved at rest: 92.972.8% with POC and
91.772.0% with LO compared to CA—87.872.7% (POC and LO vs. CA po0.05). POC and LO
signiﬁcantly improved oxygenation during 6MWT (mean SpO2 was 84.375% and
83.874.2%, respectively) compared to breathing CA—77.677.4%, po0.05. Mean 6MWT
distance increased with LO (350783m) and POC (342796m) when compared to CA
(317784m), however, these differences were not statistically signiﬁcant. Dyspnoea score
assessed at the end of the exercise (Borg scale) was signiﬁcantly lower when breathing
oxygen (4.271.2 with POC and 4.171.7 with LO vs. 5.471.9 with CA, po0.05).Elsevier Ltd. All rights reserved.
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J. Nasilowski et al.1022Conclusions: Effectiveness of oxygen supplementation from a POC did not differ from the
LO source during 6MWT in COPD patients with respiratory failure. Oxygen at 3 lpm ﬂow was
not sufﬁcient to prevent hypoxaemia during strenuous exercise.
& 2008 Elsevier Ltd. All rights reserved.Introduction
Long-term domiciliary oxygen therapy (LTOT) is one of a very
few medical procedures that prolong life of patients with
respiratory failure.1,2 More than 2 million people beneﬁt
from this form of treatment worldwide. A majority of them
use oxygen concentrators (OC) as a source of oxygen. OCs
remain the most economic way to provide oxygen at home.
To comply with physician prescription to breathe oxygen for
more than 15 h per day, patients using OCs are forced to stay
at home and to limit their outdoor activities.
Liquid oxygen (LO) overcomes that inconvenience by
combining a large stationary unit with a small portable
canister allowing the patient to leave home and to enjoy
outdoor activities while using supplementary oxygen.
A less efﬁcient combination is the use of an OC at home
and pressurized oxygen in small lightweight cylinder for
ambulation. Need for frequent reﬁlling and cumbersome
logistics make this source less convenient although less
expensive than LO. Now, portable gas cylinders can also be
safely reﬁlled from a uniquely constructed oxygen concen-
trator.3
Recently, a new ambulatory source of oxygen—portable
oxygen concentrator (POC)—has become available. Light-
weight, battery operated, systems with an integrated
oxygen-conserving device (OCD) provide a mobile oxygen
source for a few hours use. Oxygen ﬂow is set up as an
equivalent of continuous oxygen ﬂow per minute. There are
no published reports on the effectiveness of oxygen supply
provided by POCs.
The aim of the study was to determine if a POC is as
effective as LO in reducing exercise-induced hypoxaemia in
severe COPD patients on LTOT.Materials and methods
Subjects
Fifteen patients with COPD undergoing LTOT were included
in the study. COPD was diagnosed using GOLD criteria.4
Eligibility for LTOT was based on the ATS/ERS guidelines:
PaO2p55mmHg or PaO2 56–60mmHg and the ECG or
radiographic evidence of pulmonary hypertension or poly-
cythaemia with haematocrit X55%.5 Exclusion criteria
included: refusal to participate in the study, important
comorbidities (e.g. limiting angina, musculoskeletal dis-
ability and malignancy), recent (within 8 weeks) exacerba-
tion of COPD. The protocol of the study was explained to
each subject, and signed informed consent was obtained
from all patients. The study protocol was approved by the
Institutional Ethics Committee.Study design
Investigations were performed in an outpatient clinic. All
subjects underwent a series of ﬁve 6-min walk tests
(6MWT). Tests were performed in a 30-m corridor in
accordance with the ATS guidelines.6 To minimize effect of
learning, ﬁrst two sessions of 6MWT were conducted as
training sessions and involved breathing air and carrying a
3.5 kg weight, corresponding to the weight of portable
oxygen delivery devices. The last three sessions of 6MWT
were performed with one of three tested devices: POC
(4.6 kg; LifeStyle AirSep, Buffalo, NY, USA), LO cylinder
(3.3 kg; FreeLOX, Taema, France) and a cylinder with
compressed air (CA) (3.3 kg). The subjects carried the
devices themselves during the tests. Oxygen supplementa-
tion was 3 lpm for LO and an equivalent to 3 lpm for POC.
Three liters ﬂow was set on the CA cylinder. The order of
testing devices was randomly assigned. The subjects were
not aware of what type of oxygen delivery system they were
testing. Each 6MWT was administered on separate visits
several days apart. Before each test, all subjects were
allowed to rest for 30min breathing room air. Then arterial
blood was taken for blood gas analysis. Next, while resting,
the subjects were given oxygen or air supplementation from
one of the tested devices. After 10min, blood pressure,
heart rate and dyspnoea level were measured; the last one
using the Borg scale.7 Next, the subjects performed the walk
test. Arterial blood oxygen saturation (SpO2) and pulse rate
were monitored continuously with a pulse oximeter (Pulsox-
3Li, Minolta, Osaka, Japan). The oximeter recorded the
SpO2 and pulse rate every 5 s. As soon as the walk test was
completed blood pressure, heart rate and dyspnoea level
were measured again.
Data analysis
Statistical analysis was performed using Statistica 7.1 data
analysis software system (StatSoft Inc.). Results are given as
mean7SD, unless stated otherwise. Friedman’s ANOVA by
ranks followed by post hoc sign tests were used to analyse
differences between POC, LO and CA breathing. A
p-valueo0.05 was considered to be statistically signiﬁcant.
Results
Patient characteristics
In total, 13 patients completed the study (seven men and six
women; mean age 66711 years). One patient developed
exacerbation of COPD during the study and one patient
refused to participate. Their mean FEV1 was 0.7970.27 l
(35.2713.7% of predicted), FEV1/VC was 51.8711.3%,
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Figure 1 Mean SpO2 at each minute of 6MWT for the 13
subjects with tested devices. Data are presented as mean7SE.











Prescribed oxygen ﬂow in resting condition,
lpm
1.770.7
Data are presented as mean7SD, unless otherwise stated.
Deﬁnition of abbreviations:
lpm—litres per minute; BMI—body mass index; FEV1—forced
expiratory volume in one second; FEV1/FVC—forced expira-
tory volume in 1 s to forced expiratory volume ratio; RV/
TLC—residual volume to total lung capacity ratio; PaO2—
partial pressure of oxygen in arterial blood; PaCO2—partial
pressure of carbon dioxide in arterial blood.
Supplementary oxygen beneﬁts during a walk test in COPD patients 1023residual volume (RV) was 5.172 l (232798% of predicted),
RV/TLC was 70712%. Resting arterial blood gases at room
air showed a PaO2 of 52.575mmHg and a PaCO2 of
51.377.5mmHg. Demographic and clinical data of study
participants are shown in Table 1.
Walking distance
During two training walk tests, subjects covered 305791
and 315792m, respectively (p ¼ NS). The results of both
tests corresponded very closely to the distance covered
during the proper test when breathing CA—317784m.
Better results were obtained when patients were using
LO—350783m or POC—342796m. However, differences
between oxygen and air breathing were not signiﬁcant.
Breathlessness during walk tests
The level of dyspnoea while resting before the tests was
similar, ranging from 1.571.3 before the test with CA, to
1.671.4 for LO and 1.671.7 for POC. Breathlessness at the
end of exercise was signiﬁcantly lower while breathing
oxygen (4.271.2 for POC and 4.171.7 for LO) than while
breathing room air (5.471.9, po0.05).
Efﬁcacy of oxygen supplementation
Both oxygen devices assured good oxygenation at rest: the
mean SpO2 was 92.972.8% with POC and 91.772.0% using
LO, while on air SpO2 was 87.872.7% (POC and LO vs. CA
po0.05). The mean value of SpO2 during the 6MWT was
84.375% and 83.874.2% (p ¼ NS) for POC and LO,
respectively, while during air breathing SpO2 fell to
77.677.4% (POC and LO vs. CA po0.05). There were no
signiﬁcant differences in oxygenation between POC (SpO2
81.578%) and LO (SpO2 80.977.1%) at the end of the tests.The SpO2 after the CA tests was 73.2710.7%, which was
signiﬁcantly lower than SpO2 after 6MWTs with oxygen
devices (po0.05).
Comparison of desaturation time
SpO2 below 90%, 88%, 85% and 80% during 6MWT demon-
strated that the POC provided slightly better oxygenation
than LO. However, the differences were very small and
insigniﬁcant. The desaturation time was signiﬁcantly shorter
during oxygen breathing than during air breathing. For
example, time of 6MWT spent in desaturation below 88%
was present during 59736% of time during the test with
POC, 71725% for LO (p ¼ 0.08) and 87727% for CA (POC
and LO vs. CA, po0.05) and time of test spent in
desaturation below 80% was 21726% for POC, 29732% for
LO (p ¼ 0.38) and 49737% for CA (po0.05).
The same pattern of SpO2 decrease during 6MWT was
observed with all three devices. There was a steep decline
in SpO2 during the ﬁrst 3min of 6MWT followed by a plateau
towards the end of the test (Figure 1). However, SpO2 at the
end of each minute was lower during air breathing than
during oxygen breathing from both sources (po0.05).
Discussion
The need of oxygen supplementation during ambulation in
COPD patients on LTOT has already been identiﬁed by
Barach8 and Cotes and Gilson9 in the middle of the 20th
century. Those needs were fulﬁlled by the development of
portable units with LO and gaseous compressed oxygen. At
the end of the 20th century high-pressure cylinders reﬁlled
from oxygen concentrators were constructed.3 In 2002, ﬁrst
POC was introduced, followed by several other models.10
However, there are no publications about their efﬁcacy
apart from congress abstracts.11–13 We believe that our
study is the ﬁrst one comparing a new device with a well-
established source of ambulatory oxygen. We compared POC
to a LO portable unit. Both devices are designated to supply
oxygen during ambulation. The principal question was: Is
POC equally effective in reducing exercise-induced desa-
turation in patients with respiratory failure? In spite of
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devices compared, results of our study showed no statisti-
cally signiﬁcant differences in oxygenation between POC
and portable LO. The mean SpO2 during the whole test, as
well as SpO2 measured in the end of the test and at each
consecutive minute of the test were almost equal for both
devices. Despite no signiﬁcant differences, most measured
variables were slightly higher for POC than for the portable
LO. The improvement of oxygenation using LO and POC was
signiﬁcantly better when compared with air breathing.
Supplemental oxygen had no signiﬁcant inﬂuence on the
distance covered during 6MWT. Although the distance
increased by 25m with POC and 33m with LO, this
improvement did not reach level of statistical signiﬁcance
(p ¼ 0.09). This may be an effect of limited number of
studied subjects (type 2 error). Both devices signiﬁcantly
reduced breathlessness at the end of exercise.
Differences between devices
There are two principal differences between POCs and LOs.
First, a POC does not provide 100% oxygen. The concentra-
tion of oxygen ranges between 85% and 95% depending on
ﬂow rate. The higher ﬂow, the lower concentration of
oxygen, while LOs give pure, 100% oxygen at any ﬂow.
Second, the LO portable unit tested in our study gave
continuous oxygen ﬂow while the POC delivered oxygen in
pulses. POCs do not store oxygen, but produce it continu-
ously. To conserve oxygen and decrease the weight of
equipment, a POC has a built-in OCD. The bolus of low
volume oxygen is delivered to airways only during inspira-
tion.
The amount of oxygen delivered by OCDs is expressed as
‘‘equivalent’’ to continuous ﬂow. But in fact the equivalency
is not a universal value. The OCDs differ in volume and time
of oxygen delivery at the same ﬂow setting, which cause the
differences in FiO2.
14
OCD in POC tested in our study (‘‘Impulse Elite’’) is the
pulse-type device. It releases ﬁxed bolus of oxygen with the
beginning of each breath which is advantageous, while it
was shown that delivered FiO2 depends on oxygen volume
delivered in the ﬁrst 0.6 s of inhalation.15 At the setting of
3 lpm, used in our investigation, the bolus according to
manufacturer is 26.25 cm3. The total amount of inhaled
oxygen per minute depends on bolus amount and number of
breaths. This pattern of oxygen delivery raises important
issues. The main question is does it provides adequate
oxygenation, particularly during exercise?
Comparison of pulse-dose and continuous ﬂow
There are very few studies comparing both systems of
oxygen delivery. Bliss et al.14,15 using lung models suggest
that pulse-dose system could be more effective than
continuous ﬂow in delivery of oxygen during exercise. On
the other hand, Gallegos and Shigeoka16 proved in theore-
tical model that POCs may under-treat hypoxaemia,
especially during exercise mainly because of low oxygen
concentration and low bolus volume.
The studies on patients with respiratory failure also gave
controversial results. Roberts et al. compared the efﬁcacy ofa demand oxygen delivery system to continuous ﬂow. In both
systems 100% oxygen was used. The results showed that the
demand oxygen delivery system was less effective. However,
either of the systems was able to prevent desaturation.17
Lewarski et al. compared compressed concentrator gas (93%
O2) delivered via OCD to continuous ﬂow of 100% oxygen.
They found no statistically signiﬁcant differences in SpO2
between the two methods used.11 Cuvelier et al. performed
a similar study comparing concentrator-reﬁlled vs. conven-
tional pressurized oxygen cylinder, both without OCD. Even
with the differences in FiO2 delivery (94.272.6% vs.
98.874.9%, p ¼ 0.02) the mean transcutaneous oxygen
saturation showed similar improvement with both devices.3
In spite of the higher weight of POC of about 1 kg, which
must have increased the work performed by patients, our
study has revealed identical improvement in oxygenation
during exercise. That data can suggest that lighter models of
POC may be more effective during ambulation in patients on
long-term oxygen therapy.How many lpm are needed by hypoxaemic COPD
patients during exercise?
It is well known that the oxygen ﬂow preventing desatura-
tion at rest is not effective during exercise. ERS/ATS
recommendations advise augmentation of oxygen ﬂow
during exercise. The mean oxygen ﬂow prescribed for our
patients in resting condition was 1.770.7 lpm. Our study
showed that continuous ﬂow or equivalent to 3 lpm of
oxygen, which correspond approximately to doubling resting
dose, was not preventing hypoxaemia during strenuous
exercise. However, it may be sufﬁcient during less vigorous
activities of daily life. Case et al. investigated oxygenation
in hypoxaemic COPD patients during rehabilitation activ-
ities. Each patient was titrated to a POC setting that yielded
the SpO2490% during exercise. They found that both a POC
with the setting of 4.770.5, which is equivalent to lpm, and
a continuous ﬂow LO with a mean ﬂow of 3.971.3 lpm,
provided sufﬁcient oxygenation: SpO2 93% and 91%, respec-
tively.12 McCoy et al. tested three models of POC on six
COPD oxygen-dependent patients. The devices were titrated
to oxygen supplementation at rest for tested subjects.
During self-paced 10-min walk there was no signiﬁcant
desaturation. In two patients a decrease of SpO2 to 89% was
noted. There were no differences between three tested
POCs.13Conclusions
With rapid technological development more new medical
equipment becomes available including POCs. Our results
suggest that the effects of oxygen supplementation with
POCs did not differ from the LO portable units during 6MWT
in walking distance and SpO2. It appears that POCs may be
safely used for ambulatory oxygen treatment. Our data
suggests that doubling the dose of oxygen ﬂow at rest, was
not sufﬁcient to prevent hypoxaemia during strenuous
exercise and rather three-fold increase of oxygen ﬂow
should be prescribed.
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